Sign In
18 Nov 2010 07:00
18 November 2010
LSE: VER
Vernalis plc: V3381 Programme Update
Vernalis plc today announces its decision to cease further investment in V3381.
An interim review of data from the small pilot study in chronic cough being undertaken in collaboration with Professor Ashley Woodcock from the University Hospitals of South Manchester NHS Foundation revealed only marginal efficacy and some issues with tolerability. Following consideration of these results and the previously announced results of the IN-STEP Phase IIb study in neuropathic pain no further investment will be made by Vernalis in V3381.
-- ends --
Enquiries:
Vernalis Contacts
| |
Ian Garland, Chief Executive Officer | +44 (0) 118 989 9360 |
David Mackney, Chief Financial Officer
| |
Brunswick Group
| |
Jon Coles | +44 (0) 20 7404 5959 |
Justine McIlroy | |
Taylor Rafferty
| |
Rob Newman | +44 (0) 20 7614 2900 |
Faisal Kanth |
Notes to Editors
About Vernalis
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and nine candidates in development, six of which are designated priority programmes. Three of these priority programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Biogen Idec, Chiesi, Endo, GSK, Menarini, Novartis and Servier.
Product | Indication | Pre-Clinical | Phase I | Phase II | Phase III | Marketed | Marketing Rights |
Priority Programmes | |||||||
CNS Programmes | |||||||
Frovatriptan | Acute Migraine | X | Menarini & Endo Pharma | ||||
2nd generation A2A antagonist | Parkinson's Disease | X | Biogen Idec | ||||
V158866 | Pain | X | Worldwide | ||||
Oncology Programmes | |||||||
AUY922 | Cancer | X | Novartis | ||||
HSP990 | Cancer | X | Novartis | ||||
V158411 | Cancer | X | Worldwide | ||||
Other Therapeutic Areas | |||||||
V85546 | Inflammatory Disease | X | Worldwide | ||||
Legacy programmes | |||||||
V10153 | Ischaemic Stroke | X | Worldwide | ||||
RPL554 | Asthma/ Allergic Rhinitis | X | Verona Pharma | ||||
CHR2797 | Cancer | X | Chroma Therapeutics | ||||
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova® and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
Follow the stocks
